Stimulation of de novo biosynthesis of purine and pyrimidine nucleotides in the liver of rats following burn injury

Metabolism ◽  
1988 ◽  
Vol 37 (12) ◽  
pp. 1114-1119 ◽  
Author(s):  
Tohru Chikenji ◽  
Kazuko Kita ◽  
Masamiti Tatibana
1984 ◽  
Vol 160 (4) ◽  
pp. 987-1000 ◽  
Author(s):  
C C Wang ◽  
H W Cheng

Trichomonas vaginalis, a human protozoan parasite known to lack the capability of synthesizing purine and pyrimidine nucleotides de novo, was found also incapable of converting its ribonucleotides to deoxyribonucleotides. The only apparent means of providing deoxyribonucleotides for DNA synthesis relies on salvaging exogenous deoxyribonucleosides by a deoxyribonucleoside phosphotransferase activity in the T. vaginalis 10(5) g pelletable fraction. The activity, constituted by at least two isozymes I and II, can be solubilized by Triton X-100, has a pH optimum of 5.0-6.0, and recognizes only thymidine, deoxyadenosine, deoxyguanosine, and deoxycytidine as the phosphate acceptor. TMP, dAMP, dGMP, dCMP, dUMP, FdUMP, and p-nitrophenylphosphate can serve as phosphate donors. Enzyme I has been purified 10-fold by DEAE-Sepharose chromatography and Sephacryl 200 filtration, and is totally freed of the acid phosphatase of T. vaginalis. It has an estimated molecular weight of 200,000 and Km values of 2-3 mM for the four deoxyribonucleosides, which act on each other as competitive inhibitors. It also possesses phosphatase activity capable of hydrolyzing p-nitrophenylphosphate with a Michaelis constant of 0.74 mM. The rates of hydrolysis are enhanced by thymidine, which suggests that the latter may be the preferred phosphate acceptor, and Enzyme I may be, thus, more a transferase than a phosphatase. This enzyme could be a potential target for antitrichomonial chemotherapy.


Glia ◽  
1993 ◽  
Vol 7 (2) ◽  
pp. 176-182 ◽  
Author(s):  
Lisa J. Christjanson ◽  
Pamela J. Middlemiss ◽  
Michel P. Rathbone

1978 ◽  
Vol 56 (4) ◽  
pp. 227-236 ◽  
Author(s):  
Herb B. LéJohn ◽  
Linda E. Cameron ◽  
Glen R. Klassen ◽  
Renate U. Meuser

A study of [32P]orthophosphate labelling of purine and pyrimidine nucleotides and dinucleoside polyphosphates, HS3, HS2, and HS1, during ontogeny of the fungus Achlya showed that HS compounds were labelled very quickly at late stages of growth and then declined to low levels just as the overall growth decreased. At this time, sporangial formation was initiated and HS3 increased again. By contrast, the common cellular nucleotides stayed at a low constant level. When 1 mML-glutamine (D-glutamine was ineffective) was added to the growth medium at this time, sporangial formation was aborted.When cells growing in rich medium of peptone, yeast extract, and glucose were transferred to a nutrient-deficient medium of 0.1 mM CaCl2, they developed sporangia within 8 h and sporulated by 10 h. In this period, the cellular levels of HS compounds increased manyfold (HS3, 6-fold, HS2, 18-fold; and HS1, 55-fold). In the presence of 1 mML-glutamine, cellular HS decreased to barely perceptible levels and sporulation was aborted. Several antimetabolites that block de novo biosynthesis of nucleotides, diazouracil, azaserine, and methotrexate, stimulated further HS accumulation in nutrient-deficient medium but did not block sporulation. By contrast, uridine, guanosine, and adenosine caused a partial reduction of HS compounds and correspondingly delayed sporulation. Thymidine was ineffective. Actinomycin D (5 μg/ml) caused HS2 and HS1 to accumulate manyfold and inhibited sporulation. Cycloheximide (10 μg/ml) caused HS3 to increase severaifold and also blocked sporulation, in nutrient-deficient medium, it seemed necessary that all three HS compounds increase simultaneously for sporulation to occur.HS compounds proved to be powerful inhibitors of enzymes involved with nucleic-acid metabolism. They inhibited DNA-dependent RNA polymerases with HS2 being more effective than HS3; HS1 inhibited DNA polymerase specifically. This is probably meaningful as low intracellular levels of HS compounds were detected when nucleic-acid synthesis was proceeding optimally.The uracil moiety of HS compounds was labelled with [14C]aspartate, CO2, and orotate, not uracil or uridine. Neither [14C]adenine nor [14C]adenosine was incorporated into HS3. HS compounds may be biosynthesized by the de novo pathways of nucleotide biosynthesis.A role for HS compounds as 'sensors' of nitrogen insufficiency in Achlya as a prelude to sporulation is suggested by these findings.


Reproduction ◽  
2002 ◽  
pp. 757-768 ◽  
Author(s):  
EA Carrey ◽  
C Dietz ◽  
DM Glubb ◽  
M Loffler ◽  
JM Lucocq ◽  
...  

Enzymes of the pathway for de novo biosynthesis of pyrimidine nucleotides have been reported in spermatozoa from fruitfly and mammals. The aim of the present study was to test the hypothesis that the enzymes for biosynthesis of uridine monophosphate (UMP) are concentrated near the mitochondria, which are segregated in the mid-piece of spermatozoa. Baby hamster kidney fibroblasts were compared with spermatozoa from rams, boars, bulls and men. Antibodies raised against synthetic peptides from sequences of the multienzyme polypeptides containing glutamine-dependent carbamyl phosphate synthetase, aspartate transcarbamylase and dihydroorotase (CAD) and UMP synthase, which catalyse reactions 1-3 and 5-6, respectively, were used, together with an affinity-purified antibody raised against dihydroorotate dehydrogenase (DHODH), the mitochondrial enzyme for step 4. Western blot analysis, immunofluorescent microscopy and immunoelectron microscopy confirmed that CAD and UMP synthase are found in the cytoplasm around and outside the mitochondria; DHODH is found exclusively inside the mitochondria. CAD was also located in the nucleus, where it has been reported in the nuclear matrix, and in the cytoplasm, apparently associated with the cytoskeleton. It is possible that CAD in the cytoplasm has a role unconnected with pyrimidine biosynthesis.


1997 ◽  
Vol 73 ◽  
pp. 120
Author(s):  
Kazushi Kushiku ◽  
Hiromi Yamada ◽  
Kazuhiko Shibata ◽  
Ryoko Tokunaga ◽  
Katsuhiro Yamada ◽  
...  

1995 ◽  
Vol 73 (01) ◽  
pp. 039-048 ◽  
Author(s):  
A Bierhaus ◽  
Ch J Hemmer ◽  
N Mackman ◽  
R Kutob ◽  
R Ziegler ◽  
...  

SummarySerum from patients with P. falciparum malaria at day 1 (pretherapy) induces tissue factor (TF) in cultured endothelial cells. TF induction depends on de novo transcription as shown in Nuclear Run On assays. Electrophoretic mobility shift assays demonstrated binding of AP-1 and NF- κB/Rel proteins to their recognition sites in the TF promotor. After therapy (day 28), stimulation of TF antigen by patient serum is reduced by 70%. When serum obtained before and after therapy was compared, a decrease of NF-κB activation was evident. Activation of NF-κB-like proteins was in part dependent on TNFα in patient serum, since a TNFα neutralizing antibody reduced induction of TF transcription and translation and induction of NF-κB-like proteins. Induction of TF activity was suppressed by pDTC, an inhibitor of NF-κB activation. When different promotor constructs of the TF gene were tested, induction was dependent upon the presence of the intact NF-κB-like binding site in the TF promotor. A mutant with deleted NF-κB, but intact AP-1 sites was not inducible. Mutation of the AP-1 sites did not prevent induction, but reduced inducibility by pretherapy serum. Therefore, NF-κB/Rel proteins are responsible for induction of TF transcription by pretherapy serum, but AP-1 is needed for highest inducibility. The effect of antiparasitic therapy on the induction of TF by serum from patients with complicated P. falciparum malaria is dependent on a therapy-mediated loss of activation of NF-κB-like proteins in post-treatment patient serum.


Sign in / Sign up

Export Citation Format

Share Document